Apogee Therapeutics Inc (APGE)

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Apogee Therapeutics to Participate in Upcoming June Conferences

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today...

Form 8-K - Current report

Form 8-K - Current report

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and...

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart...

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material